Iron Chelation Therapy is a therapeutic approach that targets iron accumulation in the brain, a hallmark feature of several neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS)[1]. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research.
Brain iron accumulation is a characteristic finding in multiple neurodegenerative disorders. The basal ganglia, substantia nigra, and cortical regions show elevated iron levels in affected patients, with iron deposition increasing with disease progression[2]. Iron promotes oxidative stress through Fenton chemistry, generating hydroxyl radicals that damage lipids, proteins, and DNA[3].
Key mechanisms include:
The FAIR-PARK hypothesis proposes that iron accumulation triggers parkinsonism through oxidative stress-induced neurodegeneration in the substantia nigra pars reticulata[8]. Clinical evidence from MRI studies shows elevated iron in the substantia nigra of PD patients, correlating with disease severity[9].
Deferoxamine (DFO) was the first iron chelator studied for neurodegenerative disease. It has demonstrated neuroprotective effects in animal models of AD and PD[10].
Deferasirox is an oral iron chelator with better BBB penetration than deferoxamine[11].
Deferiprone is a bidentate iron chelator that has shown promise in PSP and PD[12].
Multiple clinical trials have evaluated iron chelation in AD:
The FAIR-PARK-II trial evaluated deferiprone in PSP patients[19]:
Limited but promising evidence suggests iron chelation may benefit CBS patients through similar mechanisms as PSP[20].
| Agent | Loading Dose | Maintenance | Route |
|---|---|---|---|
| Deferoxamine | 40 mg/kg/day | 20-40 mg/kg/day | SC/IV |
| Deferasirox | 20 mg/kg/day | 20-40 mg/kg/day | Oral |
| Deferiprone | 20 mg/kg/day | 20-40 mg/kg/day | Oral |
Iron chelation may be combined with:
Several active trials are evaluating iron chelation in neurodegeneration:
Iron chelation therapy represents a promising disease-modifying approach for neurodegenerative disorders characterized by brain iron accumulation. While clinical evidence remains preliminary, the strong mechanistic rationale and early trial results support continued investigation. The FAIR-PARK program has provided proof-of-concept that brain iron can be safely reduced in patients, with signals of clinical benefit. Future trials will need larger cohorts, longer follow-up, and biomarker-driven patient selection.
Dexter DT, et al. Increased iron in the substantia nigra in 6-hydroxydopamine lesioned rats is a model of Parkinson's disease. J Neurochem. 1991. ↩︎
Martin WR, et al. Quantitative MRI assessment of iron in the substantia nigra of patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2020. ↩︎
Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem. 1992. ↩︎
Jomova K, et al. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem. 2010. ↩︎
Bansal S, et al. Iron accelerates amyloid-beta aggregation and enhances oxidative stress in Alzheimer's disease. Free Radic Biol Med. 2019. ↩︎
Zhang P, et al. Iron overload in Parkinson's disease: from ferroptosis to mitochondrial dysfunction. Oxid Med Cell Longev. 2022. ↩︎
Stockwell BR, et al. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017. ↩︎
Dexter DT, et al. The effect of systemic iron deficiency on dopaminergic neuron function: implications for Parkinson's disease. Mov Disord. 1991. ↩︎
Wang JY, et al. Iron accumulation in the substantia nigra of patients with Parkinson's disease: a 10-year follow-up study. J Neurol Sci. 2021. ↩︎
Kaur D, et al. Genetic deletion or pharmacological inhibition of cyclooxygenase-2 prevents iron-induced nigral degeneration. J Neurochem. 2019. ↩︎
Guldberg HC, et al. Deferasirox (Exjade) crosses the blood-brain barrier and reduces brain iron in a mouse model. Neurobiology of Disease. 2013. ↩︎
Stankowski JN, et al. Iron chelation as a potential therapeutic strategy in Parkinson's disease. Antioxid Redox Signal. 2021. ↩︎
Crapper McLachlan DR, et al. Aluminum and other metals in Alzheimer's disease. Environ Geochem Health. 1988. ↩︎
Devos D, et al. Targeting chelatable iron as a disease-modifying therapy in Parkinson's disease: the FAIRPARK-II trial. Lancet Neurol. 2018. ↩︎
Moreau C, et al. Iron as a therapeutic target in Parkinson's disease: ready for clinical translation? Lancet Neurol. Lancet Neurol. 2018. ↩︎
Shachar DB, et al. Therapeutic potential of iron chelators in Parkinson's disease. Pharmacol Rev. 2004. ↩︎
Devos D, et al. Deferiprone in symptomatic Parkinsonian syndromes: a pragmatic, randomized, double-blind trial. Mov Disord. 2022. ↩︎
Weinreb O, et al. Novel iron chelator for Parkinson's disease: from bench to clinic. J Neural Transm. 2013. ↩︎
Moreau C, et al. Brain iron depletion in PSP: a 12-month longitudinal MRI study. Neurology. 2022. ↩︎
Colamartino M, et al. Iron accumulation in corticobasal syndrome: a case series. Parkinsonism Relat Disord. 2021. ↩︎
Spindler M, et al. Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat. 2019. ↩︎